Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
In a research report published Monday, Kumar highlighted his skepticism surrounding the company's Fast Track designation of Coversin, a therapy for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients who have polymorphisms conferring eculizumab resistance. Specifically, the analyst highlighted the fact that Akari's stock soared nearly 130 percent since the announcement, but the market may have mistaken the designation to cover Coversin in PNH generally.
"We are very proud of the continued advancement of our Coversin program for the treatment of PNH in patients with or without polymorphisms," Gur Roshwalb, CEO of Akari Therapeutics said in a press release. "The FDA fast track designation recognizes the unmet need in patients with PNH who cannot be treated with the current standard of care due to polymorphisms."
Not So Fast
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Kumar pointed out a 2014 study, which found that only 3.2 percent of PNH patients had Soliris resistance mutations. Moreover, for a disease with an incidence rate of 1.3 per million, Soliris-resistant PNH represents just 10 to 20 patients in the US per year.
As such, the analyst emphasized that Akari's designation represents "an extremely limited subset of PNH patients" and most certainly isn't for the broader indication.
Shares remain Sell rated but with a price target boosted from $5 to $6.50 on the analyst's model updates.
At last check in Monday's pre-market session, shares of Akari were down 8.86 percent at $14.60.
Related Links:Akari Therapeutics Reaches Double-Digits After FDA Ruling For ConversinClovis Shares Reiterated As A Sell Following 10% RallyCrypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.